Rating Change
Canaccord Genuity analysts initiated coverage on Incyte Corporation (NASDAQ:INCY) with a rating of Buy on August 20, 2026.
new coverageNASDAQ:INCY
Canaccord Genuity Initiates Coverage on Incyte Corporation (INCY) with Buy
Canaccord Genuity analysts initiated coverage on Incyte Corporation (NASDAQ:INCY) with a rating of Buy on August 20, 2026.
At publication ·
What changed
Incyte Corporation (NASDAQ:INCY) · new coverage
- Firm
- Canaccord Genuity
- Rating
- Buy
- Price at event
- $127.22
- Market capitalization
- $18.9B
At a glance
Key takeaways
- Canaccord Genuity initiated Buy coverage on Incyte Corporation (INCY) on August 20, 2026, with the stock trading at $127.22 and a market capitalization of $18.9 billion.
Market Context
Incyte Corporation operates in the Healthcare sector. The stock currently trades at $127.22 with a market capitalization of $18.9B. The stock has gained 21.8% over the past 52 weeks.
Analyst coverage from Canaccord Genuity provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Incyte Corporation.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Incyte Corporation
Among the 10 most recent ratings: 8 Buy, 2 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 20, 2026 | Canaccord Genuity | Buy | N/A |
| Aug 20, 2026 | HC Wainwright & Co. | Buy | N/A |
| Aug 17, 2026 | Piper Sandler | Overweight | N/A |
| Aug 04, 2026 | Mizuho | Outperform | N/A |
| Aug 03, 2026 | Leerink Partners | Outperform | N/A |
Related Tools: Analyst Ratings Dashboard | View INCY Stock Page
Frequently Asked Questions
What does the Buy rating mean for INCY?
A rating of Buy from Canaccord Genuity reflects the analyst's outlook on Incyte Corporation (NASDAQ:INCY). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the INCY forecast page.
